AI Insight
This commentary addresses the challenge of choosing between multiple established treatment options when direct comparative evidence from randomized controlled trials is lacking. Treatments are often individually validated against placebo or a common comparator, but not directly compared to each other, creating gaps in evidence-based decision-making. The authors use the example of respiratory syncytial virus prevention in infants, where maternal vaccination and infant monoclonal antibodies have both proven effective versus placebo but have never been directly compared in trials.
Why it matters
Without head-to-head comparisons between commonly used treatments, physicians and patients lack the robust evidence needed to make fully informed treatment decisions. This evidence gap is widespread across medical practice and highlights the need for trials designed specifically to compare existing treatment options rather than only testing new interventions against placebo.
Understand the Science
In many disease settings, physicians and patients can choose between several treatment options that are in common use, but how should they make the choice? The problem is often not the absence of evidence but the absence of robust randomised controlled evidence directly comparing treatments that are already widely used in practice. Treatment options might have been directly compared with a common comparator, but not to each other; for example, in respiratory syncytial virus prevention in infants, both maternal vaccination and infant monoclonal antibodies have shown efficacy versus placebo but have not been directly compared.
Source: [Comment] Tailoring levels of evidence in trials comparing common treatments